Propanc Biopharma, Inc. (PPCB) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$0.66

From 52W high−98.89%

Volume156814.00

Market cap$1.39M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$0.66

From 52W high

−98.89%

Volume

156814.00

Market cap

$1.39M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

P/E (TTM)

—

RSI (14)

35.5

MomentumView details →

1D Return

−3.17%

YTD Return

−95.21%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.1x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−186.82%

ROA (TTM)

−128.10%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+95.47%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+98.95%

EBITDA YoY

+67.73%

MomentumView details →

1D Return

−3.17%

YTD Return

−95.21%

1Y Return

−98.81%

RSI (14)

35.5

vs 50D SMA

−45.93%

vs 200D SMA

−86.43%

Capital & dividendView details →

Debt/Equity

0.16x

Current Ratio

2.37x

Quick Ratio

2.37x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.28

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−18.36M

Op. CF (TTM)

−4.11M

Latest newsMore news →

Propanc Biopharma announced plans to commence a world-first Phase 1b first-in-human study of its drug candidate PRP in February 2027.11d ago

Propanc Biopharma announced it has commenced finalization of a clinical trial protocol and will conduct a feasibility assessment for its First-In-Human Phase 1b clinical study of PRP in up to 40 advanced cancer patients with solid tumors.33d ago

Similar companies

Iterum Therapeutics plcITRM Abpro CorporationABP Liminatus Pharma, Inc. WarrantsLIMNW Avenue Therapeutics, Inc.ATXI YD Bio Limited WarrantsYDESW NeuroSense Therapeutics Ltd.NRSNW Find similar companies →

Latest newsMore news →

Propanc Biopharma announced plans to commence a world-first Phase 1b first-in-human study of its drug candidate PRP in February 2027.11d ago Propanc Biopharma announced it has commenced finalization of a clinical trial protocol and will conduct a feasibility assessment for its First-In-Human Phase 1b clinical study of PRP in up to 40 advanced cancer patients with solid tumors.33d ago Propanc Biopharma announced positive preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma models, showing over 90% tumor growth inhibition and significant survival benefit.45d ago